Acurx Pharmaceuticals (ACXP) Expected to Announce Earnings on Friday

Acurx Pharmaceuticals (NASDAQ:ACXP) is anticipated to release its Q4 2025 results before the market opens on Friday, March 13th. Analysts expect the company to announce earnings of ($1.01) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 8:00 AM ET.

Acurx Pharmaceuticals Trading Down 4.6%

NASDAQ:ACXP opened at $1.45 on Friday. The firm has a market capitalization of $3.70 million, a PE ratio of -0.17 and a beta of -1.16. Acurx Pharmaceuticals has a 1 year low of $1.41 and a 1 year high of $21.00. The firm’s fifty day simple moving average is $2.30 and its 200 day simple moving average is $3.88.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 28th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Acurx Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $31.00.

Institutional Trading of Acurx Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Acurx Pharmaceuticals in the fourth quarter valued at $27,000. Geode Capital Management LLC acquired a new position in shares of Acurx Pharmaceuticals in the 4th quarter valued at $31,000. Millennium Management LLC bought a new position in shares of Acurx Pharmaceuticals during the 4th quarter worth about $103,000. Finally, Armistice Capital LLC bought a new stake in Acurx Pharmaceuticals in the second quarter valued at about $551,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).